Preliminary results of neoadjuvant chemotherapy in resectable gastric cancer
- 30 October 2026
- journal article
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 15 (5)
Abstract
Neoadjuvant chemotherapy (NAC) for resectable gastric cancer (GC) has demonstrated benefits in survival rates in key studies. The safety and risks of neoadjuvant chemotherapy (NAC) remain a matter of debate. Objective. Evaluate the immediate results of chemotherapy in resectable gastric cancer. Material and methods. The retrospective analysis included 247 patients who underwent combined treatment for resectable GC. 149 patients went to the NAC group, 98 patients to the adjuvant chemotherapy (AC) group. Complications were assessed using the Clavien-Dindo intraoperative risk scale, the degree of pathomorphological response was assessed using the Mandart scale, and adherence to AC was determined. Results. Complications of NAC were reported in 36 (24.2%) patients, and no cases of severe toxicity or mortality were detected. A pronounced pathomorphological effect (TRG 1—2) was detected in 37 (25.0%) patients. Clinically significant postoperative complications (Clavien-Dindo>II) were reported in 9.4% in the NAC group and in 15.3% in the AC group. Pathomorphological stage I was registered in 30.9% of the NAC group compared with 5.1% in the AC group (p<0.001). Conclusion. Conducting NACT in gastric cancer demonstrates an acceptable toxicity profile and provides a pronounced pathomorphological effect without increasing surgical risks.Keywords
This publication has 14 references indexed in Scilit:
- Treatment discontinuation associated with perioperative toxicity of FLOT versus XELOX chemotherapy in patients with resectable gastric cancer: prospective randomized trial (PECORINO)Journal of Gastrointestinal Oncology, 2025
- A comprehensive overview of gastric cancer management from a surgical point of viewBiomedical Journal, 2024
- Neoadjuvant chemotherapy with FLOT scheme in surgical treatment of gastric cancer: short- and long-term outcomes. A retrospective cohort studyJournal of Modern Oncology, 2024
- Comparison of the efficacy of neoadjuvant chemotherapy with FLOT regimen and adjuvant chemotherapy with XELOX/FOLFOX regimen in patients with locally advanced gastric cancer: A retrospective studyJournal of Modern Oncology, 2024
- Toxicity analysis during neoadjuvant induction chemotherapy and subsequent chemoradiotherapy in patients with locally advanced gastric cancerP.A. Herzen Journal of Oncology, 2024
- ANALYSIS OF SAFETY OF NEOADJUVANT CHEMORADIOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED GASTRIC CANCER (RESULTS OF A MULTICENTER RANDOMIZED TRIAL)Siberian journal of oncology, 2020
- Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trialThe Lancet, 2019
- Perioperative chemotherapy for gastric cancer: the current stateJournal of Modern Oncology, 2018
- Mismatch Repair Deficiency, Microsatellite Instability, and SurvivalJAMA Oncology, 2017
- Neoadjuvant chemotherapy in the combined treatment of gastric cancerP.A. Herzen Journal of Oncology, 2014